Published on 19/11/2025

ICFs, Assent & Short Forms in Practice: Step-by-Step Guide for Sponsors, CROs and Sites

The ethical execution of clinical trials is paramount, especially in studies involving vulnerable populations. Informed Consent Forms (ICFs), assent, and short forms are essential documents in this regard. This guide provides a comprehensive, step-by-step approach tailored for sponsors, Contract Research Organizations (CROs), and investigative sites engaged in clinical trials—specifically, focusing on non-small cell lung cancer clinical trials. It also incorporates insights on significant clinical trials such as the Aegean clinical trial and the Mariposa clinical trial.

Understanding Informed Consent and Regulatory Framework

Informed consent is a foundational ethical and legal requirement in clinical research. It ensures participants understand the study’s purpose, procedures, risks, and rights. In the US, this requirement is governed primarily by the FDA’s regulations (21 CFR Part 50), and in Europe, by the General Data Protection Regulation (GDPR) and the Clinical Trials Regulation (EU No. 536/2014). In the UK, both the MHRA and local ethics committees provide oversight.

ICFs must be written in clear, layman’s terms and comprehensively detail various elements such as:

• The study purpose and duration.
• Procedures involved and the individual’s role.
• Potential risks and benefits.
• Confidentiality of records.
• Right to withdraw from the study at any time.

Each jurisdiction has specific requirements concerning language, content, and format. For instance, the FDA recommends incorporating an “informed consent process” rather than merely presenting a document, thus making it a dynamic, interactive exchange.

ICFs and Assent: Key Differences

Understanding the distinction between informed consent and assent is vital for compliance, particularly when involving minors or individuals with cognitive impairments. Informed consent is obtained from legally authorized representatives (typically parents or guardians in the case of minors), while assent is obtained from the minor participant themselves.

Assent should involve an age-appropriate understanding of the trial’s essentials and can be documented through a simplified assent form. It is crucial to make sure the assent process respects the participant’s autonomy, indicating respect for their developing rights as decision-makers.

Drafting and Reviewing ICFs

The preparation of an ICF requires collaboration among various stakeholders, including clinical operations, regulatory affairs, and legal teams. Below is a detailed step-by-step approach to drafting ICFs for clinical trials, specifically focusing on non-small cell lung cancer clinical trials:

Step 1: Determine Core Components

Every ICF must contain essential components tailored to specific study protocols, informed by guidance from ICH-GCP. Besides the basic contents mentioned previously, the document should address:

• Specific designations of risks associated with the treatment of non-small cell lung cancer.
• Explanation of any placebo or active comparator treatment.
• Details about additional procedures, such as biopsies or imaging, which may be part of the clinical trial.

Step 2: Use Plain Language

ICFs should be drafted in plain language, avoiding medical jargon. This is critical to ensure comprehension among diverse populations. The language should match the reading level of the target participants, potentially including translations for non-English speakers.

Step 3: Align with Local Regulations

Review local regulations from recognized entities such as the [FDA](https://www.fda.gov) in the US, EMA in the EU, and MHRA in the UK to ensure compliance with specific regional requirements. Pay close attention to the IRB/REC requirements, which may dictate additional content or formatting rules.

Step 4: Involve Stakeholders in Review

Engage stakeholders early in the review process. Input from clinical teams, legal experts, and ethics committees can provide valuable insights. Conduct iterative reviews to enhance clarity and correct potential ambiguities.

Step 5: Pilot Testing

Consider conducting cognitive interviews with a small group of your target population to test the ICF’s understandability and comprehensiveness. Gather feedback and refine the document as necessary before final approval.

Short Forms and Their Use in Clinical Trials

Short forms serve as alternative methods for obtaining informed consent, particularly in situations where a standard ICF is impractical. They are typically used in conjunction with a fuller written ICF. Short forms summarize key information and often specify the intention to provide the complete ICF upon request.

In line with Good Clinical Practice (GCP) guidance, ensure that the process for using short forms adheres strictly to the following:

• The participant is provided with the opportunity to ask questions about the trials and is encouraged to discuss them with a family member or guardian.
• A full ICF version is available to participants for review at any point.
• A suitable resource is available for the understanding of complex treatment regimes, especially in areas such as non-small cell lung cancer clinical trials.

Special Considerations in Vulnerable Populations

When conducting trials involving vulnerable populations, such as children or patients with limited decision-making capacity, additional precautionary measures must be taken:

Step 1: Assess Decisional Capacity

Evaluate the participant’s ability to understand the information presented. In cases of cognitive impairment or youth, an advocate or legally authorized representative (LAR) should be involved in the consent process.

Step 2: Training for Recruiters

Investigators and site personnel must be trained to approach these participants with sensitivity. They should also be equipped to recognize cues indicating confusion or discomfort in the choice-making process.

Step 3: Monitoring and Compliance

Regular audits and monitoring should be established to ensure proper adherence to consent procedures, targeting common ethical challenges observed in methodologies, especially highlighting vulnerable groups.

Documenting the Informed Consent Process

Documentation is a critical aspect of the informed consent process and must be performed meticulously. This includes proper electronic records or paper logs that detail:

• The date and time the consent was obtained.
• The identity of the individual who conducted the informed consent discussion.
• Any questions posed by the participant and their responses.

Ensure that all consent forms—whether full or short—are securely stored and can be easily retrieved during inspections or audits by regulatory authorities. The efficient management of consent documentation is a hallmark of thorough site management organization clinical research protocols.

Conclusion: Best Practices for Sponsors and CROs

In conclusion, navigating the complexities surrounding ICFs, assent, and short forms in clinical trials is essential for operational success and regulatory compliance. By implementing a thorough, systematic approach, sponsors and CROs can ensure that informed consent processes are ethical, transparent, and participant-friendly.

Delving into non-small cell lung cancer clinical trials brings added layers of responsibility given the intense treatment and monitoring involved. Adhering to established regulatory frameworks and employing best practices in the drafting, review, and execution of informed consent is fundamental. Moreover, it is imperative to stay updated on evolving guidelines from organizations like the FDA, EMA, and MHRA to maintain compliance and safeguard the well-being of participants.